Could common antioxidants help thalassemia patients?

NCT ID NCT07157722

Not yet recruiting Disease control Sponsor: Tanta University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This Phase 3 trial tests whether two antioxidant supplements, N-acetyl cysteine and alpha-lipoic acid, can improve blood vessel health and reduce oxidative stress in adults with beta thalassemia. Sixty-six participants will take one of the supplements or a placebo alongside their usual treatment for 12 weeks. The study focuses on changes in artery thickness and blood markers of inflammation and oxidative damage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: N-acetyl cysteine and alpha-lipoic acid
What this could lead to: If it works, this could point toward a simple, low-cost way to reduce heart-related complications in people with beta thalassemia.
What could go wrong: This is a small, early-stage trial with only 66 participants, and the outcomes are mainly lab markers, not direct health benefits. The supplements may not produce meaningful clinical improvements.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BETA-THALASSEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

beta thalassemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BETA-THALASSEMIA

Contacts and locations

Locations

Faculty of Pharmacy - Tanta University

Tanta, 31511, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.